Canada markets close in 5 minutes

Canntab Therapeutics Limited (TBF1.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.4560+0.0080 (+1.79%)
As of 8:06AM CEST. Market open.

Canntab Therapeutics Limited

223 Riviera Drive
Markham, ON L3R 5J6
Canada
289-301-3812
http://canntab.ca

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Jeffrey W. RenwickCo-Founder, Pres, Head of Production & DirectorN/AN/A1970
Mr. Richard C. GoldsteinCo-Founder, CFO & DirectorN/AN/A1961
Mr. Barry M. PolisukChairman & Corp. Sec.N/AN/A1960
Mr. Lawrence LatowskyChief Exec. OfficerN/AN/A1961
Mr. Joshi LaxminarayanChief Scientific OfficerN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Canntab Therapeutics Limited researches and develops advanced pharmaceutical grade formulations of cannabinoids and terpenes in Canada. It offers sustained release, immediate release, modified release, flash melt, and bi-layered tablets for treating sleep disorders, posttraumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.

Corporate Governance

Canntab Therapeutics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.